BioXcel Therapeutics Inc
BTAI1.799USD
+0.429+31.30%
Market hours （ET）Quotes delayed by 15 min
9.84MMarket Cap
LossP/E TTM
More Details of BioXcel Therapeutics Inc Company
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Company Info
Ticker SymbolBTAI
Company nameBioXcel Therapeutics Inc
IPO dateMar 08, 2018
CEODr. Vimal Mehta, Ph.D.
Number of employees37
Security typeOrdinary Share
Fiscal year-endMar 08
Address555 Long Wharf Dr
CityNEW HAVEN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code06511-6107
Phone12036438060
Websitehttps://www.bioxceltherapeutics.com/
Ticker SymbolBTAI
IPO dateMar 08, 2018
CEODr. Vimal Mehta, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
Mr. Erik Kopp
Mr. Erik Kopp
Investor Relations
Investor Relations
--
--
DR. Frank D. Yocca ,Ph.D.
DR. Frank D. Yocca ,Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Vimal Mehta, Ph.D.
Dr. Vimal Mehta, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
19.80K
+373.89%
Mr. David J. Mack
Mr. David J. Mack
Independent Director
Independent Director
18.62K
+10.00%
Dr. Michal Votruba, M.D., Ph.D.
Dr. Michal Votruba, M.D., Ph.D.
Independent Director
Independent Director
11.52K
--
Dr. Peter Mueller, Ph.D.
Dr. Peter Mueller, Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
7.49K
-42.90%
Mr. Javier Rodriguez
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
Senior Vice President, Chief Legal Officer, Corporate Secretary
6.66K
+301.39%
Mr. Richard I. Steinhart
Mr. Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
6.44K
+346.98%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jul 24
Updated: Thu, Jul 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
Shareholders
Shareholders
Proportion
Bioxcel Corp
7.93%
Armistice Capital LLC
4.76%
Murchinson Ltd.
2.25%
UBS Financial Services, Inc.
1.68%
Goldman Sachs & Company, Inc.
0.41%
Other
82.97%
Shareholder Types
Shareholders
Proportion
Corporation
7.93%
Hedge Fund
4.76%
Investment Advisor
2.76%
Investment Advisor/Hedge Fund
2.62%
Individual Investor
1.28%
Research Firm
0.89%
Other
79.75%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
225
1.20M
19.77%
-199.41K
2025Q1
248
1.19M
19.87%
-219.94K
2024Q4
260
1.00M
33.25%
-269.93K
2024Q3
269
724.21K
25.25%
-802.39K
2024Q2
282
1.14M
44.29%
-598.60K
2024Q1
282
1.17M
59.63%
-354.60K
2023Q4
282
1.17M
63.22%
-360.50K
2023Q3
290
1.23M
67.44%
-639.74K
2023Q2
289
1.71M
93.56%
-204.68K
2023Q1
297
1.69M
93.06%
-56.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bioxcel Corp
480.34K
7.93%
-53.83K
-10.08%
Jun 06, 2024
Armistice Capital LLC
288.13K
4.76%
-24.20K
-7.75%
Mar 31, 2025
Murchinson Ltd.
136.08K
2.25%
+136.08K
--
Mar 31, 2025
UBS Financial Services, Inc.
101.78K
1.68%
+21.97K
+27.53%
Mar 31, 2025
Goldman Sachs & Company, Inc.
24.79K
0.41%
+24.79K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
22.87K
0.38%
-508.00
-2.17%
Mar 31, 2025
Geode Capital Management, L.L.C.
22.06K
0.36%
+2.56K
+13.15%
Mar 31, 2025
Mehta (Vimal)
4.18K
0.07%
+382.00
+10.06%
Jun 15, 2025
Beacon Pointe Advisors LLC
18.84K
0.31%
+18.84K
--
Mar 31, 2025
The Vanguard Group, Inc.
18.82K
0.31%
+18.82K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
ProShares UltraPro Russell2000
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
iShares Morningstar Small-Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
WisdomTree Artificial Intelligence and Innov Fund
0%
View more
ProShares Hedge Replication ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
WisdomTree Artificial Intelligence and Innov Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Date
Type
Ratio
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
Feb 06, 2025
Merger
16<1
